Goserelin

Summary

Goserelin (CHEMBL1201247) is an approved protein (ATC L02AE03) targeting GNRHR; indicated across 16 conditions including neoplasm and uterine corpus leiomyoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: L02AE03
• Targets: 1 (GNRHR)
• Indications: 16 conditions
• Clinical trials: 203
• Chemistry: 1269.4 Da · C59H84N18O14

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201247
Name	Goserelin
Type	Protein
Max phase	4
FDA approved	yes
PubChem CID	5311128
ATC	L02AE03
Molecular formula	C59H84N18O14
Molecular weight	1269.4
InChIKey	BLCLNMBMMGCOAS-URPVMXJPSA-N

SMILES: CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6

IUPAC name: (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide

Also known as: Goserelin, Goserelina, Gosereline, ICI 118,630, ICI-118630, goserelin, GOSERELIN, GOSERELINE, Goserelin Acetate

Parent form; salt/anhydrous children: CHEMBL1200501

Patent coverage: 18,854 distinct patent families (80,573 SureChEMBL compound mentions), from 7 matched compound structure(s). One matched structure accounts for 80,445 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
GNRHR	GnRH1 receptor	Full agonist		0.1%	P30968

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): GNRHR.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
Hormone ligand-binding receptors	1	GNRHR
G alpha (q) signalling events	1	GNRHR

Dominant GO biological processes

GO term	Targets
G protein-coupled receptor signaling pathway	1
gonadotropin secretion	1
cellular response to hormone stimulus	1
signal transduction	1
cellular response to gonadotropin-releasing hormone	1

Indications & clinical

Indications

6 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
neoplasm	4	MONDO:0005070	EFO:0000616
prostate carcinoma	3	MONDO:0005159	EFO:0001663
breast carcinoma	3	MONDO:0004989	EFO:0000305
prostate adenocarcinoma	3	MONDO:0005082	EFO:0000673
breast neoplasm	3	MONDO:0021100	EFO:0003869
metastatic prostate carcinoma	3	MONDO:0004956	EFO:0000196

8 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
uterine corpus leiomyoma	3	MONDO:0007886	EFO:0000731
infertility disorder	3	MONDO:0005047	EFO:0000545
Hodgkins lymphoma	2	MONDO:0004952	EFO:0000183
metabolic syndrome X	2	MONDO:0011565	EFO:0000195
adenomyosis	2	MONDO:0010888	EFO:1001757
invasive lobular breast carcinoma	2	MONDO:0005051	EFO:0000553
primary ovarian failure	2	MONDO:0005387	HP:0008209
salivary gland cancer	2	MONDO:0004669	MONDO:0004669

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 203.

Phase distribution

Phase	Trials
PHASE2	93
PHASE3	65
Not specified	16
PHASE1	12
PHASE4	7
PHASE1/PHASE2	5
PHASE2/PHASE3	4
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05161195	PHASE4	ACTIVE_NOT_RECRUITING	Roll-over Study to Allow Continued Access to Ribociclib
NCT06455969	PHASE4	RECRUITING	Adaptions and Resiliency to Multi-Stressor OpeRations
NCT00255268	PHASE4	WITHDRAWN	CMAB vs IMAB in Metastatic Prostate Cancer
NCT00293670	PHASE4	UNKNOWN	FINNPROSTATE Study VII: Intermittent Versus Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer
NCT00851461	PHASE4	COMPLETED	Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy
NCT01738724	PHASE4	TERMINATED	Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin
NCT04248621	PHASE4	UNKNOWN	Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients
NCT01674140	PHASE3	ACTIVE_NOT_RECRUITING	S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
NCT02115282	PHASE3	ACTIVE_NOT_RECRUITING	Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
NCT02344472	PHASE3	ACTIVE_NOT_RECRUITING	Detect V / CHEVENDO (Chemo vs. Endo)
NCT02535221	PHASE3	RECRUITING	Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer
NCT02685397	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Management of Castration-Resistant Prostate Cancer with Oligometastases
NCT03678025	PHASE3	RECRUITING	Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
NCT04423211	PHASE3	RECRUITING	Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
NCT04455750	PHASE3	ACTIVE_NOT_RECRUITING	A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
NCT04484818	PHASE3	ACTIVE_NOT_RECRUITING	Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
NCT04513717	PHASE3	ACTIVE_NOT_RECRUITING	Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NCT04787744	PHASE2/PHASE3	RECRUITING	Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
NCT05050084	PHASE3	ACTIVE_NOT_RECRUITING	Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NCT05781217	PHASE3	RECRUITING	Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624
NCT05827081	PHASE3	RECRUITING	Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
NCT00002460	PHASE3	UNKNOWN	Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer
NCT00002580	PHASE3	COMPLETED	Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer
NCT00002582	PHASE3	COMPLETED	Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer
NCT00002633	PHASE3	COMPLETED	Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer
NCT00002651	PHASE3	COMPLETED	SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer
NCT00002881	PHASE3	COMPLETED	Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer
NCT00003653	PHASE3	COMPLETED	Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
NCT00004124	PHASE3	COMPLETED	S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
NCT00004635	PHASE3	COMPLETED	Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer
NCT00014586	PHASE3	TERMINATED	Bicalutamide Compared With Observation Followed by Bicalutamide Plus Either Goserelin or Orchiectomy in Treating Patients With Prostate Cancer
NCT00021450	PHASE3	COMPLETED	Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer
NCT00047099	PHASE3	COMPLETED	Combination Chemotherapy in Treating Women With Breast Cancer
NCT00053911	PHASE3	TERMINATED	Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer
NCT00055731	PHASE3	COMPLETED	Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse
NCT00067015	PHASE3	COMPLETED	Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer
NCT00068601	PHASE3	COMPLETED	S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
NCT00104715	PHASE3	COMPLETED	Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer
NCT00295646	PHASE3	COMPLETED	Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
NCT00303784	PHASE3	UNKNOWN	Prostate Adenocarcinoma TransCutaneous Hormones
NCT00309478	PHASE3	COMPLETED	Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients
NCT00388804	PHASE3	TERMINATED	External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer
NCT00423475	PHASE3	COMPLETED	Radiation Therapy With or Without Goserelin in Treating Patients Who Have Undergone Surgery for Recurrent or Refractory Prostate Cancer
NCT00427245	PHASE3	COMPLETED	Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer
NCT00429403	PHASE3	TERMINATED	Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer
NCT00439751	PHASE3	COMPLETED	Immediate Versus Deferred Androgen Deprivation Therapy,Goserelin for Recurrent Prostate Cancer After Radical Radiotherapy
NCT00541047	PHASE3	COMPLETED	RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery
NCT00605267	PHASE3	COMPLETED	Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment
NCT00651326	PHASE3	TERMINATED	Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer
NCT00767286	PHASE3	COMPLETED	Goserelin, Flutamine, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
NCT00769548	PHASE3	COMPLETED	Radiation Therapy and Hormone Therapy in Treating Patients With Prostate Cancer
NCT00831233	PHASE3	TERMINATED	Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer
NCT00833248	PHASE3	COMPLETED	Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
NCT00849082	PHASE3	COMPLETED	Radiation Therapy With or Without Goserelin and Cyproterone in Treating Patients With Prostate Cancer
NCT00884273	PHASE3	COMPLETED	Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients
NCT00888082	PHASE3	WITHDRAWN	Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients With Chemotherapy
NCT00912548	PHASE3	UNKNOWN	Evaluating the Role of the Addition of Ovarian Function Suppression (OFS) to Tamoxifen in Young Women
NCT00946920	PHASE3	COMPLETED	A Trial of Degarelix in Patients With Prostate Cancer
NCT01242748	PHASE3	TERMINATED	A Degarelix Trial in Patients With Prostate Cancer
NCT01530607	PHASE3	COMPLETED	Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
NCT01744366	PHASE3	COMPLETED	One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population
NCT01964170	PHASE3	COMPLETED	A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer
NCT02003209	PHASE3	COMPLETED	Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
NCT02132390	PHASE3	UNKNOWN	Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea
NCT02278120	PHASE3	COMPLETED	Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
NCT02483767	PHASE3	COMPLETED	Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer
NCT02914158	PHASE3	UNKNOWN	Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women
NCT02941926	PHASE3	COMPLETED	Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
NCT03070886	PHASE2/PHASE3	COMPLETED	Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
NCT03096847	PHASE3	COMPLETED	Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer
NCT03373708	PHASE2/PHASE3	UNKNOWN	Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer
NCT03423199	PHASE3	UNKNOWN	PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY
NCT03447132	PHASE3	COMPLETED	Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant
NCT04478266	PHASE3	TERMINATED	Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer
NCT05438810	PHASE3	UNKNOWN	This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
NCT05439499	PHASE3	UNKNOWN	This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
NCT00544830	PHASE2	ACTIVE_NOT_RECRUITING	Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
NCT01723774	PHASE2	ACTIVE_NOT_RECRUITING	PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
NCT01786265	PHASE2	ACTIVE_NOT_RECRUITING	Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer
NCT02476786	PHASE2	RECRUITING	Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
NCT02592083	PHASE2	ACTIVE_NOT_RECRUITING	Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors
NCT02603679	PHASE2	ACTIVE_NOT_RECRUITING	Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases
NCT03361735	PHASE2	ACTIVE_NOT_RECRUITING	Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
NCT03942653	PHASE2	RECRUITING	Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma
NCT04734730	PHASE2	RECRUITING	Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
NCT05003752	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate Cancer
NCT05513365	PHASE2	RECRUITING	Phase II Dutasteride in Combination With CAB vs CAB in SDC
NCT05582499	PHASE2	RECRUITING	Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
NCT05594095	PHASE2	RECRUITING	SNF Platform Study of HR+/ HER2-advanced Breast Cancer
NCT05607004	PHASE2	RECRUITING	(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
NCT05720260	PHASE2	RECRUITING	Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
NCT06145308	PHASE2	RECRUITING	Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
NCT06225284	PHASE2	RECRUITING	Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients
NCT06348134	PHASE2	RECRUITING	Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
NCT06378866	PHASE2	RECRUITING	Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
NCT06387056	PHASE2	RECRUITING	Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)
NCT06575257	PHASE2	RECRUITING	Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer
NCT06953882	PHASE2	RECRUITING	Impact of Omitting Chemo Based on Patient’s Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy
NCT07158021	PHASE2	RECRUITING	Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial
NCT07287098	PHASE2	NOT_YET_RECRUITING	A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

14 molecules share ≥1 primary target. Top 14 by shared-target count:

Molecule	Source	Status	Shared targets
CETRORELIX	ChEMBL + PubChem	Phase 4 (approved)	GNRHR
DEGARELIX	ChEMBL + PubChem	Phase 4 (approved)	GNRHR
ELAGOLIX	ChEMBL + PubChem	Phase 4 (approved)	GNRHR
GANIRELIX	ChEMBL + PubChem	Phase 4 (approved)	GNRHR
RELUGOLIX	ChEMBL + PubChem	Phase 4 (approved)	GNRHR
ABARELIX	ChEMBL	Phase 4 (approved)	GNRHR
GONADORELIN	ChEMBL	Phase 4 (approved)	GNRHR
LEUPROLIDE	ChEMBL	Phase 4 (approved)	GNRHR
LINZAGOLIX	ChEMBL	Phase 4 (approved)	GNRHR
ACYLINE	ChEMBL	Phase 2	GNRHR
SUFUGOLIX	ChEMBL	Phase 2	GNRHR
Belzutifan	PubChem	Approved	GNRHR
Deslorelin	PubChem	Approved	GNRHR
Triptorelin	PubChem	Approved	GNRHR